» Articles » PMID: 11727961

Clinical Relevance of Biologic Factors in Male Breast Cancer

Overview
Specialty Oncology
Date 2001 Dec 1
PMID 11727961
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

There is ample information on the clinical role of biologic factors in female breast cancer: urokinase-type plasminogen activator (uPA), its receptor uPAR, its inhibitors PAI-1 and PAI-2, cathepsin D and pS2-protein. However such reports are missing or very rare for male breast cancer. We determined the cytosolic levels of oestrogen receptor (ER), progesterone receptor (PgR), cathepsin D, pS2-protein, uPA, uPAR, PAI-1 and PAI-2 of the primary tumour tissues from 40 male breast cancer patients. The tumour levels were compared with those of 180 matched females and 4114 historic females with breast cancer. In male breast tumours the level of PgR was higher, those of uPA, PAI-1, PAI-2 and cathepsin D lower. The tumour level of ER in men was similar to those in the matched and postmenopausal women, but much higher than those in the historic women. Male breast cancer seems to be biologically different from female breast cancer. Correlation of the eight cell biologic factors with disease outcome showed that PAI-1 (p = 0.03) was the only independent predictive factor for poor prognosis in male breast cancer.

Citing Articles

Therapeutic Management in Elderly Male Breast Cancer Patients: A Scoping Review.

Di Rito A, Grillo A, Carbonara R Curr Oncol Rep. 2025; 27(2):120-134.

PMID: 39826033 DOI: 10.1007/s11912-024-01629-z.


Current state of surgical management for male breast cancer.

Popa-Nimigean V, Ahmed M Transl Cancer Res. 2022; 8(Suppl 5):S457-S462.

PMID: 35117123 PMC: 8798217. DOI: 10.21037/tcr.2019.04.09.


Male Breast Cancer Review. A Rare Case of Pure DCIS: Imaging Protocol, Radiomics and Management.

Tari D, Morelli L, Guida A, Pinto F Diagnostics (Basel). 2021; 11(12).

PMID: 34943439 PMC: 8700459. DOI: 10.3390/diagnostics11122199.


Epidemiology and practice patterns for male breast cancer compared with female breast cancer in Japan.

Ishii T, Nakano E, Watanabe T, Higashi T Cancer Med. 2020; 9(16):6069-6075.

PMID: 32613775 PMC: 7433825. DOI: 10.1002/cam4.3267.


The Management and Outcomes of Male Breast Cancer.

Uslukaya O, Gumus M, Gumus H, Bozdag Z, Turkoglu A J Breast Health. 2017; 12(4):165-170.

PMID: 28331756 PMC: 5351442. DOI: 10.5152/tjbh.2016.3073.